Adalta Ltd has released a press release.
R&D Tax Incentive Refund received
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from AdAlta
- Quarterly Appendix 4C and Activities Report
- AD-214 program update, cash runway extension
- European Patent for AD-214 granted
- BIO International Convention presentation
- AdAlta presentation at Bioshares Biotech Summit
Later from AdAlta
- 1AD & GPCR Therapeutics to evaluate CXCR4 i-bodies in cancer
- Balance of R&D Tax Incentive Refund received
- AD-214 progress and priorities
- AD-214 progress and priorities webinar presentation
- Second Japan patent for AD-214
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta